Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials

Gottlieb, Alice B.; Gordon, Kenneth B.; Hsu, Sylvia; Elewski, Boni E.; Eichenfield, Lawrence F.; Kircik, Leon; Rastogi, Shipra; Pillai, Radhakrishnan; Israel, Robert J.

doi:10.1111/jdv.14913

Cited by 26 publications

(18 citation statements)

References 25 publications

(74 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pruritus-reducing effects of biologic treatment on psoriatic pruritus have been reported (393)(394)(395)(396)(397)(398)(399)(400)(401). One single report of cases referred to persistent CP (402).…”

Section: 411mentioning

confidence: 99%

European S2k Guideline on Chronic Pruritus

Weißhaar¹,

Szepietowski²,

Dalgard³

et al. 2019

Acta Derm Venerol

250

201

View full text Add to dashboard Cite

ActaDV is a journal for clinical and experimental research in the field of dermatology and venereology and publishes highquality papers in English dealing with new observations on basic dermatological and venereological research, as well as clinical investigations. Each volume also features a number of review articles in special areas, as well as Correspondence to the Editor to stimulate debate. New books are also reviewed. The journal has rapid publication times.

show abstract

Section: 411mentioning

confidence: 99%

European S2k Guideline on Chronic Pruritus

Weißhaar¹,

Szepietowski²,

Dalgard³

et al. 2019

Acta Derm Venerol

250

201

View full text Add to dashboard Cite

show abstract

“…When reporting the PSI, patients rate the itch during the previous 24 hours from 0 (not at all) to 4 (very severe). Gottlieb and colleagues13 analysed PSI itch scores from across AMAGINE-1/-2/-3 and reported that this improved with brodalumab 140 and 210 mg doses, starting at week 2 and sustained through week 12. The PSI itch response associated with brodalumab 210 mg was greater than that of ustekinumab through to week 12, and at week 52 for patients who remained on constant treatment with either therapy after re-randomisation 13…”

Section: Brodalumab Clinical Efficacy Datamentioning

confidence: 99%

Brodalumab in psoriasis: evidence to date and clinical potential

Foulkes¹,

Warren²

2019

DIC

View full text Add to dashboard Cite

Brodalumab is a recombinant, fully human monoclonal antibody (IgG2) which binds with high affinity to the interleukin (IL) 17 receptor A (IL17R). Brodalumab is now licensed and approved for the treatment of moderate-to-severe chronic plaque psoriasis in North America and Europe. As the third to market in the class of agents targeting IL-17, we review its place in the expanding armamentarium of cytokine-directed therapies for patients with severe psoriasis. Brodalumab is a highly efficacious therapy for psoriasis, whose mechanism of action is separate from other treatments targeting IL-17. Its use is associated with rapid control of the disease. We suggest that brodalumab is likely to be considered in those patients requiring rapid control of disease, where there is no known history of depression or suicidal ideation.

show abstract

“…The PSI total score is the sum of the eight items and can range from 0 to 32. Assessment and validation of the PSI have shown strong internal consistency, test-retest reliability and responsiveness to changes in clinical studies [13,15].…”

Section: Introductionmentioning

confidence: 99%

Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL)

Lacour¹,

Bewley

Hammond

et al. 2020

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction: Clinical trials have shown that psoriasis patients who achieve complete skin clearance are more likely to report no impairment in health-related quality of life (HRQoL) and no psoriasis symptoms versus patients who achieve almost complete skin clearance. However, real-world data are lacking. The objective of this study was to estimate the real-world proportion of moderate-to-severe psoriasis patients on biologic treatment who Digital Features To view digital features for this article go to

show abstract

Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials

Abstract: Brodalumab demonstrated rapid, robust improvements in symptoms assessed by the PSI, including itch, vs. placebo and ustekinumab.

Cited by 26 publications

References 25 publications

European S2k Guideline on Chronic Pruritus

European S2k Guideline on Chronic Pruritus

Brodalumab in psoriasis: evidence to date and clinical potential

Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL)

Contact Info

Product

Resources

About